Biopol Chemicals IPO Review

Live status (30 Jun 2026): A modest listing that didn't hold. The IPO was subscribed about 22x, but the grey market premium stayed near zero throughout, and the stock listed at ₹111 on 13 February 2026 only a small premium to the ₹108 issue price then slipped below it, trading around ₹96 now. So despite decent subscription, IPO investors are sitting on a small loss four plus months on.

About the Company

Behind a soft cotton shirt, a smooth fabric finish or a clean industrial mould lies a specialty chemical doing the work. Biopol Chemicals makes those the silicones, emulsifiers and additives that other manufacturers use in textiles, home care, agriculture and industry.

Incorporated in 2023 though built on an older chemicals proprietorship it took over Biopol manufactures and distributes specialty chemicals across four categories: silicones, emulsifiers, biochemicals and polyelectrolytes. It has a portfolio of 66 products, the bulk of them silicone based, used in textile softeners and finishes, home care cleaning chemicals, farm surfactants and industrial release agents.

It runs a pure B2B model, selling to institutional and industrial clients rather than consumers, through direct sales and distributors, with some exports to Bangladesh's large textile sector. It operates from establishments in Gujarat and West Bengal, with a manufacturing unit capable of about 18.25 lakh litres a year. It's a small, young operation with only around 24 employees. Track its live price and listing data on the IPO GMP Live homepage.

Financial Snapshot

The growth optics look strong at first, but there's a wrinkle. Revenue jumped from ₹17 crore in FY24 to ₹49 crore in FY25 a big leap but that partly reflects the company being very young and absorbing an acquired business, so it's not clean like for like growth. The first half of FY26 brought another ₹49 crore, suggesting the run rate has stepped up.

Profit has moved up too ₹2.96 crore in FY24 to ₹4.33 crore in FY25, with ₹6 crore already in the nine months to December 2025. So the bottom line is genuinely improving.

At the ₹108 issue price, the IPO was valued at roughly 20 times earnings a full price for a tiny, two year old chemicals maker. The market evidently agreed it was rich: the stock managed only a small listing pop to ₹111 and then drifted below the issue price to around ₹96.

What I'd keep front of mind is how new and how small this is. A company incorporated in 2023, built on a taken over proprietorship, with 24 employees and a short track record, simply hasn't been tested through a full cycle. The numbers are heading the right way, but there isn't much history to lean on.

Strengths

• Profit and revenue are climbing. Net profit rose to ₹6 crore in the nine months of FY26, already above full year FY25, and revenue has stepped up to a higher run rate. The direction of travel is clearly positive.
• It has a broad product range. A portfolio of 66 specialty chemical products across silicones, emulsifiers, biochemicals and polyelectrolytes lets it serve several industries textiles, home care, agriculture and industrial rather than depending on one.
• It earns export revenue. Sales into Bangladesh, a global textile manufacturing hub, give Biopol a foothold beyond India and tie it to a large, steady end market for textile chemicals.
• The IPO funds tangible assets. Proceeds go toward acquiring industrial land and repaying debt real, balance sheet strengthening uses rather than vague "general purposes."

Risks

• It's slipped below its issue price. Despite a 22x subscription, the stock listed at just ₹111 and has fallen to around ₹96 below the ₹108 issue price. The flat grey market premium correctly hinted the demand was thinner than the subscription number suggested.
• It's very young and very small. Incorporated only in 2023 and built on an acquired proprietorship, with about 24 employees, Biopol has a short track record and hasn't been tested through a downturn.
• The growth isn't clean. The jump from ₹17 crore to ₹49 crore of revenue partly reflects the business being newly formed and absorbing an acquired operation, so it's hard to judge the true underlying growth rate.
• It's a small player in a giant's market. Specialty chemicals is dominated by far larger, deep pocketed companies, and as a thinly traded SME, Biopol's stock can be volatile and hard to exit quickly.

Should You Buy, Hold, or Sell?

It's listed, and it's been a slight disappointment a small pop to ₹111, then a drift below the ₹108 issue price to around ₹96. This is a call on a tiny, fast growing but unproven specialty chemicals maker.

Conservative investors — avoid. A two year old SME with a short track record and a stock already below issue price isn't where steady money belongs.

Moderate investors — skip for now. If you want to track it, wait for two or three more quarters that show the higher revenue run rate is sustainable, not a one off from the acquisition.

Aggressive investors — only with money you can afford to lock away. The growth and export angle are interesting, but you're betting on a very young company holding its momentum.

Honest take: profits are rising and the niche is real, but this is a tiny, two year old business priced fully at IPO the market has already nudged it below issue price, and there's little track record to justify chasing it.

IPO Objects of the Issue

This was a 100% fresh issue of ₹29.63 crore, with no offer-for-sale, so all proceeds go to the company.

Contact Details

Biopol Chemicals Ltd. Registered office in Gujarat; manufacturing unit, corporate office and warehouse in West Bengal Managing Director: Santanu Sarkar

IPO Registrar — Bigshare Services Pvt. Ltd. 📞 +91-22-6263 8200 📧 ipo@bigshareonline.com 🌐 www.bigshareonline.com

Lead Manager: Smart Horizon Capital Advisors Pvt. Ltd.

Related IPO reviews: Vivid Electromech IPO · Rajnandini Fashion India IPO · Waterways (Cordelia Cruises) IPO · Ather Energy IPO · Reliance Jio IPO

This page is not investment advice. GMP is indicative only. Please consult a SEBI-registered financial advisor before investing.